BioDelivery Sciences International, Inc. (BDSI): Price and Financial Metrics
Today's Latest Price: $4.93 USD
May 22 4:00pm Add BDSI to Watchlist Sign Up POWR Components:
Buy & Hold Grade
Peer Grade Industry Rank BDSI Stock Summary The price/operating cash flow metric for Biodelivery Sciences International Inc is higher than 94.17% of stocks in our set with a positive cash flow. In terms of twelve month growth in earnings before interest and taxes, Biodelivery Sciences International Inc is reporting a growth rate of -165.42%; that's higher than merely 9.92% of US stocks. Revenue growth over the past 12 months for Biodelivery Sciences International Inc comes in at 102.56%, a number that bests 94.64% of the US stocks we're tracking. Stocks that are quantitatively similar to BDSI, based on their financial statements, market capitalization, and price volatility, are RXN, XPO, WWE, SF, and HX. BDSI's SEC filings can be seen here. And to visit Biodelivery Sciences International Inc's official web site, go to www.bdsi.com. BDSI Price/Volume Stats
492.53M BioDelivery Sciences International, Inc. (BDSI) Company Bio
BioDelivery Sciences International, Inc. engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company was founded in 1997 and is based in Raleigh, North Carolina.
BDSI Latest News Stream
All News Types Corp. News Downgrade Earnings Hedge Fund Mgmt Change New Coverage (Bullish) New Coverage (Neutral) Product News PT Lowered PT Raised PT Set (Bullish) Rating Reiterated (Bullish) Resumes Coverage (Bullish) Trump Upgrade
Event/Time News Detail Loading, please wait... Latest BDSI News From Around the Web
Below are the latest news stories about Biodelivery Sciences International Inc that investors may wish to consider to help them evaluate BDSI as an investment opportunity.
BioDelivery (BDSI) delivered earnings and revenue surprises of 400.00% and 15.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
First Quarter Total Company Net Sales Increased 94% versus Prior Year to $38.3 Million First Quarter BELBUCA® Net Sales Increased 79% versus Prior Year to $33.5 Million.
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RALEIGH, N.C., April 28, 2020 -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with.
Q4 2019 BioDelivery Sciences International Inc Earnings Call
Read More 'BDSI' Stories Here
BDSI Price Returns
-60.15% Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.9009 seconds.